Prothrombin residues 473-487 contribute to factor Va binding in the prothrombinase complex.

J Biol Chem

Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA.

Published: November 2004

To identify sequences in prothrombin (fII) involved in prothrombinase complex (fXa.fVa.fII.phospholipids) assembly, synthetic peptides based on fII sequences were prepared and screened for their ability to inhibit factor Xa (fXa)-induced clotting of normal plasma. The fII peptide (PT473-487, homologous to chymotrypsin residues 149D-163) potently inhibited plasma clotting assays and prothrombinase activity, with 50% inhibition of 12 and 10 microm peptide, respectively. Prothrombinase inhibition by PT473-487 was factor Va (fVa)-dependent and sequence-specific, because the peptide did not inhibit fII activation in the absence of fVa, and a scrambled sequence peptide, PT473-487SCR, was not inhibitory. Peptide PT473-487 did not inhibit the amidolytic activities of fXa and thrombin, suggesting that the peptide did not alter the integrity of their active sites. To determine whether PT473-487 interacted directly with fVa, fluorescein-labeled fVa (Fl-fVa) was prepared. When PT473-487 was titrated into samples containing phospholipid-bound Fl-fVa, the peptide increased fluorescein anisotropy (EC(50) at 3 microm peptide), whereas the control peptide PT473-487SCR did not alter the anisotropy, suggesting a direct binding interaction between PT473-487 and Fl-fVa. These functional and spectroscopic data suggest that fII residues 473-487 provide fVa-binding sites and mediate interactions between fVa and fII in the prothrombinase complex.

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M406645200DOI Listing

Publication Analysis

Top Keywords

prothrombinase complex
12
peptide
9
residues 473-487
8
peptide pt473-487
8
microm peptide
8
peptide pt473-487scr
8
fii
6
pt473-487
6
prothrombinase
5
prothrombin residues
4

Similar Publications

Examining downstream effects of concizumab in hemophilia A with a mathematical modeling approach.

J Thromb Haemost

November 2024

Department of Mathematics, University of North Carolina at Chapel Hill, Chapel Hill, NC; Computational Medicine Program, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. Electronic address:

Background: Tissue factor (TF) pathway inhibitor (TFPI) is an anticoagulant protein that inhibits factor (F)Xa, the TF-FVIIa-FXa complex, and early forms of the prothrombinase complex. Concizumab is a monoclonal antibody that blocks FXa inhibition by TFPI and reduces bleeding in hemophilia.

Objectives: To examine how concizumab impacts various reactions of TFPI to restore thrombin generation in hemophilia A using mathematical models.

View Article and Find Full Text PDF

Back to basics: the coagulation pathway.

Blood Res

October 2024

Daisy Hill Hospital, 5 Hospital Road, Newry, BT35 8DR, UK.

The classic coagulation cascade model of intrinsic and extrinsic coagulation pathways, i.e. contact activation pathway and tissue factor pathway, has been widely modified.

View Article and Find Full Text PDF

Rapid and ordered cleavage of prothrombin by Hopsarin D in the absence of phospholipid membranes.

J Thromb Haemost

November 2024

Department of Haematology, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom. Electronic address:

Background: Thrombin is produced by the prothrombinase complex, composed of factor (f)Xa and fVa on a phospholipid (PL) membrane surface. Snakes of the Elapidae family have venom versions of these factors that cause coagulopathy in prey. Group C venoms contain both fⅩa and fⅤa orthologues.

View Article and Find Full Text PDF

Kinetic analysis of prothrombinase assembly and substrate delivery mechanisms.

J Theor Biol

November 2024

Center for Theoretical Problems of Physico-Chemical Pharmacology, Russian Academy of Sciences, 30 Srednyaya Kalitnikovskaya str., Moscow 109029, Russia; National Medical Research Centre of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev, 1 Samory Mashela St, 117198 Moscow, Russia. Electronic address:

Prothrombinase complex, composed of coagulation factors Xa (FXa) and Va (FVa) is a major enzyme of the blood coagulation network that produces thrombin via activation of its inactive precursor prothrombin (FII) on the surface of phospholipid membranes. However, pathways and mechanisms of prothrombinase formation and substrate delivery are still discussed. Here we designed a novel mathematical model that considered different potential pathways of FXa or FII binding (from the membrane or from solution) and analyzed the kinetics of thrombin formation in the presence of a wide range of reactants concentrations.

View Article and Find Full Text PDF

Conformation of factor Xa in solution revealed by single-molecule spectroscopy.

J Thromb Haemost

October 2024

Edward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, St. Louis, Missouri, USA. Electronic address:

Article Synopsis
  • * The research utilized single-molecule Förster resonance energy transfer to investigate the structure of FXa, revealing that it behaves similarly in free form and when bound to physiologic substrates.
  • * Results suggest major conformational changes in FXa occur when calcium is absent, indicating that vitamin K antagonists could affect its structure by disrupting the Gla domain’s interaction with calcium ions.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!